Javascript must be enabled to continue!
Formulation and evaluation of lovastatin loaded nanosponges
View through CrossRef
Nanotechnology mediated drug delivery has been reported to enhance the drug efficacy, bioavailability, reduced toxicity and improve patient compliance by targeting the cells and tissues to elicit the desired pharmacological action. The main aim of the study was to formulate lovastatin loaded nanosponges and to evaluate them. Lovastatin loaded nanosponges were prepared by Emulsion solvent diffusion method using different polymers (Ethyl cellulose, Polyvinyl alcohol, β-cyclodextrin, Pluronic F68, Hydroxy Propyl β- cyclodextrin). The FTIR test is conducted as the preliminary test, by this test there was no interaction between the drug and polymers. Then nanosponges were evaluated for particle size, PDI, zeta potential, SEM, entrapment efficiency and invitro drug release. The particle size ranged from 295.5 to 578.8 nm, PDI ranged from 0.189 to 0.465, zeta potential from -17.3 to -35.96 mV and entrapment efficiency was ranged from 78.38 to 95.77 %. The cumulative percentage release from all nanosponges varied from 66.86 to 96.60% after 12 hours depending upon the drug and polymers ratio andF6 formulation showed highest drug release i.e., 96.60%. The release kinetic studies showed that the release first order diffusion controlled and the n value (0.6017) from the Korsmeyer-Peppa’s model indicated the release mechanism was non-fickian type.
Title: Formulation and evaluation of lovastatin loaded nanosponges
Description:
Nanotechnology mediated drug delivery has been reported to enhance the drug efficacy, bioavailability, reduced toxicity and improve patient compliance by targeting the cells and tissues to elicit the desired pharmacological action.
The main aim of the study was to formulate lovastatin loaded nanosponges and to evaluate them.
Lovastatin loaded nanosponges were prepared by Emulsion solvent diffusion method using different polymers (Ethyl cellulose, Polyvinyl alcohol, β-cyclodextrin, Pluronic F68, Hydroxy Propyl β- cyclodextrin).
The FTIR test is conducted as the preliminary test, by this test there was no interaction between the drug and polymers.
Then nanosponges were evaluated for particle size, PDI, zeta potential, SEM, entrapment efficiency and invitro drug release.
The particle size ranged from 295.
5 to 578.
8 nm, PDI ranged from 0.
189 to 0.
465, zeta potential from -17.
3 to -35.
96 mV and entrapment efficiency was ranged from 78.
38 to 95.
77 %.
The cumulative percentage release from all nanosponges varied from 66.
86 to 96.
60% after 12 hours depending upon the drug and polymers ratio andF6 formulation showed highest drug release i.
e.
, 96.
60%.
The release kinetic studies showed that the release first order diffusion controlled and the n value (0.
6017) from the Korsmeyer-Peppa’s model indicated the release mechanism was non-fickian type.
Related Results
TINJAUAN LOVASTATIN DAN APLIKASINYA
TINJAUAN LOVASTATIN DAN APLIKASINYA
Lovastatin is a drug belonging to statins group that is used to decrease the cholesterol levels in blood. The action mechanism of lovastatin is inhibition of the activity of HMG-Co...
Characterization of chitosan/alginate/lovastatin nanoparticles and investigation of their toxic effects in vitro and in vivo
Characterization of chitosan/alginate/lovastatin nanoparticles and investigation of their toxic effects in vitro and in vivo
AbstractIn this study, chitosan and alginate were selected to prepare alginate/chitosan nanoparticles to load the drug lovastatin by the ionic gelation method. The synthesized nano...
GW24-e1881 Effect of polydatin on peritoneal macrophage-derived foam cells of apolipoprotein E gene knockout mice
GW24-e1881 Effect of polydatin on peritoneal macrophage-derived foam cells of apolipoprotein E gene knockout mice
Objectives
Polydatin, one of the major active ingredients in Rhizoma Polygonl Cuspidatl, has been recently shown to possess extensive cardiovascular pharmacologic...
Abstract 1766: Effects of lovastatin on the PRL-3 cascade of events in prostate cancer
Abstract 1766: Effects of lovastatin on the PRL-3 cascade of events in prostate cancer
Abstract
Phosphatase of Regenerating Liver 3 (PRL-3) has recently been demonstrated to play a role in the cellular processes associated with cancer metastasis and ha...
FORMULATION AND EVALUATION OF AMPHOTERICIN B LOADED NANOSPONGES FOR TOPICAL DELIVERY
FORMULATION AND EVALUATION OF AMPHOTERICIN B LOADED NANOSPONGES FOR TOPICAL DELIVERY
In this work, solvent evaporation was used to create nanosponges, which were then combined with Amphotericin B to create a gel. The Nanosponges formulations were made utilising the...
Utilization of an Industry Byproduct, Corymbia maculata Leaves, by Aspergillus terreus to Produce Lovastatin
Utilization of an Industry Byproduct, Corymbia maculata Leaves, by Aspergillus terreus to Produce Lovastatin
Due to its ability to lower cholesterol levels, simvastatin is a leading drug for the prevention of strokes and heart disease: it also lowers the incidence of neurodegenerative dis...
Lovastatin Induces Platelet Apoptosis
Lovastatin Induces Platelet Apoptosis
Abstract
Introduction
Lovastatin, the inhibitors of 3-hydroxy 3-methylglutaryl coenzyme A (HMG-CoA) reductase, is widely used in treatments of coronar...
Preparation, physicochemical characterization, and In vivo evaluation of miconazole nitrate nanosponges for the treatment of systemic mycoses
Preparation, physicochemical characterization, and In vivo evaluation of miconazole nitrate nanosponges for the treatment of systemic mycoses
Miconazole is a Biopharmaceutics Classification System (BCS) class II drug, thus limiting its oral bioavailability. Nanosponges can improve the oral bioavailability of poorly solub...

